Condition: Hereditary Leiomyomatosis and Renal Cell Carcinoma · Papillary Renal Cell Carcinoma · Renal Cell Carcinoma · Sponsor: National Cancer Institute (NCI)
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Suspended |
| Emory University Hospital Midtown | Atlanta, Georgia, United States | Recruiting |
| Emory University Hospital/Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Emory Saint Joseph's Hospital | Atlanta, Georgia, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Suspended |
| National Institutes of Health Clinical Center | Bethesda, Maryland, United States | Suspended |
| NCI - Center for Cancer Research | Bethesda, Maryland, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Suspended |
| NYU Langone Hospital - Long Island | Mineola, New York, United States | Active Not Recruiting |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York, New York, United States | Active Not Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Suspended |
| University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh, Pennsylvania, United States | Suspended |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04981509